Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii

BACKGROUND: Tigecycline, with broad in vitro antibacterial activity, has been widely used off-label for nosocomial pneumonia caused by multi-drug resistant Acinetobacter baumannii (MDRAB). However, many concerns have been raised about the efficacy of tigecycline treatment as the inconsistent results...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yangang, Chen, Xumin, Xu, Ping, Zhu, Yan, Wang, Kuangguo, Xiang, Daxiong, Wang, Feng, Banh, Hoan Linh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482491/
https://www.ncbi.nlm.nih.gov/pubmed/31023357
http://dx.doi.org/10.1186/s40360-019-0300-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482491/
https://www.ncbi.nlm.nih.gov/pubmed/31023357
http://dx.doi.org/10.1186/s40360-019-0300-3

Ejemplares similares